Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment.
Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment.
复制标题
DOI：
10.1155/2011/542358
复制
发表时间：
2011
影响因子：
--
通讯作者：
Remick SC
中科院分区：
文献类型：
--
作者：
Nagaiah G;Hossain A;Mooney CJ;Parmentier J;Remick SC
甲状腺未分化癌是一种少见的甲状腺恶性肿瘤。只有1-2%的甲状腺癌是间变性的，但这种疾病占死亡率的14-50%，中位生存期为3 - 5个月。大多数被诊断患有这种疾病的患者年龄在65岁或以上。甲状腺癌的发病率在全球范围内呈下降趋势。大多数患者表现为颈部肿块迅速增大、吞咽困难或声音改变。我们使用PubMed进行了一次全面的文献检索，重点是甲状腺间变性癌的治疗，包括治疗和结局的历史回顾以及新药物和方法的研究。共审查了16项病历回顾性和回顾性研究以及11项前瞻性研究和/或临床试验。目前的标准治疗方法是在诊断时将疾病视为全身性疾病，并在可行的情况下进行联合肿瘤细胞减灭术和/或同时或顺序放化疗的综合治疗。阿霉素是最常用的药物，有效率为22%。目前有几名新特工正在接受调查。需要转诊患者参加临床试验。
Anaplastic thyroid cancer (ATC) is an uncommon malignancy of the thyroid. Only 1-2% of thyroid cancers are anaplastic, but the disease contributes to 14–50% of the mortality with a median survival of 3 to 5 months. Most patients diagnosed with this disease are 65 years of age or older. The incidence of anaplastic thyroid cancer is decreasing worldwide. Most patients present with a rapidly growing neck mass, dysphagia, or voice change. We performed a comprehensive literature search using PubMed focusing on the treatment of anaplastic thyroid cancer including historical review of treatment and outcomes and investigations of new agents and approaches. A total of sixteen chart review and retrospective studies and eleven prospective studies and/or clinical trials were reviewed. The current standard therapeutic approach is to consider the disease as systemic at time of diagnosis and pursue combined modality therapy incorporating cytoreductive surgical resection where feasible and/or chemoradiation either concurrently or sequentially. Doxorubicin is the most commonly used agent, with a response rate of 22%. Several new agents are currently under investigation. Referral of patients for participation in clinical trials is needed.
登录
查看更多内容
DOI：
10.1200/jco.2007.15.9566
发表时间：
2008-10-10
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Cohen EE;Rosen LS;Vokes EE;Kies MS;Forastiere AA;Worden FP;Kane MA;Sherman E;Kim S;Bycott P;Tortorici M;Shalinsky DR;Liau KF;Cohen RB
通讯作者：
Cohen RB
影响因子：
4.8
作者：
Furuya, F;Shimura, H;Kobayashi, T
通讯作者：
Kobayashi, T
影响因子：
6.6
作者：
Ain, KB;Egorin, MJ;DeSimone, PA
通讯作者：
DeSimone, PA
DOI：
10.1002/hed.21257
发表时间：
2010-07-01
影响因子：
2.9
作者：
Bhatia, Aarti;Rao, Archana;Schwartz, David L.
通讯作者：
Schwartz, David L.
影响因子：
4
作者：
Catalano, Maria G.;Fortunati, Nicoletta;Boccuzzi, Giuseppe
通讯作者：
Boccuzzi, Giuseppe